128
Disease stabilization vs. response after bevacizumab treatment in recurrent ovarian cancer: how do we determine clinical efficacy?
Sunday, March 29, 2015: 3:05 PM
Salon C-D (Hilton Chicago)
K. C. Fuh1, A. A. Secord2, K. S. Bevis3, W. K. Huh3, K. Blansit4, E. Rosenfeld5, L. Hu5, R. A. Previs6, A. B. Gardner4, D. S. Kapp7 and J. K. Chan8
1Washington University School of Medicine, St Louis, MO, 2Duke University Medical Center, Durham, NC, 3University of Alabama at Birmingham, Birmingham, AL, 4Palo Alto Medical Foundation Research Institute, Palo Alto, CA, 5California Pacific Medical Center Research Institute, San Francisco, CA, 6The University of Texas MD Anderson Cancer Center, Houston, TX, 7Stanford University, Stanford, CA, 8California Pacific & Palo Alto Medical Foundation / Sutter Research Institute, San Francisco, CA
